Plus Therapeutics, INC

Plus Therapeutics, Inc. has entered into an Equity Distribution Agreement with Canaccord Genuity LLC to sell up to $17.35 million in common stock via an at-the-market offering.

Plus Therapeutics stockholders approved all proposals at the 2026 Annual Meeting, including director elections and the 2020 Stock Incentive Plan amendment.

Plus Therapeutics reports Q1 2026 financial results, highlighting CNSide commercial progress and REYOBIQ clinical milestones.

Plus Therapeutics announced it has regained compliance with Nasdaq's minimum bid price requirement following a recent reverse stock split.

Plus Therapeutics, Inc. announced the appointment of Dr. Eric J. Daniels as Chief Development Officer, effective April 20, 2026, bringing extensive experience in pharmaceutical development.

Plus Therapeutics announced its drug REYOBIQ has received Orphan Drug Designation from the FDA for treating pediatric malignant gliomas, a rare and aggressive brain cancer.

Plus Therapeutics reports Q1 2026 financial results, highlighting progress in clinical trials and diagnostic commercialization.

Plus Therapeutics reported a significant increase in cash and working capital, driven by recent financings, while advancing its radiotherapeutic pipeline and diagnostic platform, despite an increased net loss and ongoing Nasdaq bid price compliance challenges.

Plus Therapeutics reported a significant increase in cash and a shift to positive stockholders' equity in Q2 2025, driven by recent capital raises, despite ongoing operational losses and Nasdaq listing challenges.

Plus Therapeutics, a radiotherapeutics company, reported a significant increase in net loss for Q1 2025, alongside progress in its REYOBIQ clinical trials and ongoing efforts to address multiple Nasdaq listing deficiencies.

Plus Therapeutics reported its Q3 2024 financial results, highlighting ongoing clinical trials and efforts to regain Nasdaq compliance.

Plus Therapeutics reported its second quarter 2024 results, highlighting ongoing clinical trials and a recent private placement, while also addressing concerns about its financial position and Nasdaq listing compliance.

Plus Therapeutics reports significant net losses and going concern doubts for fiscal year 2025, while advancing its CNS cancer radiopharmaceutical and diagnostic pipeline with key clinical milestones and commercial agreements.

Plus Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include information previously omitted from Part III, Items 10 through 14, and updates the exhibit list and share outstanding information.

Plus Therapeutics' 2024 10-K filing details ongoing clinical trials for REYOBIQ, acquisition of the CNSide Platform, and efforts to secure additional funding amidst financial uncertainties.

Plus Therapeutics' annual 10-K filing highlights the company's continued losses, reliance on external funding, and strategic focus on developing targeted radiotherapeutics for central nervous system cancers.

Ronald Andrews, a Director at Plus Therapeutics, Inc., reported the vesting of 922 Restricted Stock Units (RSUs) on July 1, 2026, as per SEC Form 4 filing.

Kyle Guse, a Director at Plus Therapeutics, Inc., acquired 922 shares of common stock through the vesting of Restricted Stock Units.

Plus Therapeutics, Inc. director An van Es-Johansson reported the vesting of 922 Restricted Stock Units (RSUs) on July 1, 2026.

Marc Hedrick, CEO of Plus Therapeutics, reports on the vesting of Restricted Stock Units (RSUs) on July 1, 2026, increasing his beneficial ownership of common stock.

An van Es-Johansson, a Director at PLUS THERAPEUTICS, INC., has acquired restricted stock units and stock options.

Richard J. Hawkins, a Director at Plus Therapeutics, Inc., acquired stock options and restricted stock units on May 14, 2026.

Plus Therapeutics, Inc. outlines its 2026 strategic plan for CNS cancer therapeutics and diagnostics, alongside proposals for its Annual Meeting including director elections and a significant stock incentive plan amendment.

Plus Therapeutics, Inc. filed a supplement to its definitive proxy statement to correct an inadvertent error regarding the voting standard for its Reverse Stock Split Proposal.

Plus Therapeutics, a biotechnology company focused on CNS cancers, is seeking shareholder approval for a significant capital raise and a reverse stock split to address Nasdaq listing compliance while advancing its radiotherapeutic pipeline and CNSide diagnostic platform.

Plus Therapeutics is urging its stockholders to vote on several critical proposals, including a reverse stock split, an increase in authorized shares, and warrant amendments, at a special virtual meeting on May 2, 2025.

Plus Therapeutics is holding a special meeting of stockholders to vote on proposals including a reverse stock split, authorization of warrant issuances, an increase in authorized common stock, and an extension of warrant terms.

Plus Therapeutics issues a supplement to its definitive proxy statement to clarify the number of shares available for grant under the 2015 New Employee Incentive Plan.

Plus Therapeutics, Inc. filed an S-1MEF to increase its public offering of units and pre-funded units by an additional $2.875 million, bringing the total offering to $17.25 million.

Plus Therapeutics, a radiotherapeutics and diagnostics company, is launching a public offering of units and pre-funded units to raise capital, while navigating ongoing Nasdaq listing compliance challenges and advancing its cancer treatment pipeline.

Plus Therapeutics, Inc. filed an S-1 registration statement to register up to 33 million shares for resale by Lincoln Park Capital Fund, LLC, enabling access to up to $50 million in gross proceeds for working capital and general corporate purposes.

Plus Therapeutics, Inc. has entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing the company to sell up to $50 million of its common stock over 36 months, a move expected to cause substantial dilution to existing shareholders.

Plus Therapeutics, Inc. has filed an S-1 registration statement to register the resale of up to 17,000,000 shares of common stock to Lincoln Park Capital Fund, LLC, potentially raising up to $50 million in gross proceeds for working capital and general corporate purposes, while facing a 'going concern' qualification from its auditors.

Plus Therapeutics has filed an amendment to its S-1 registration statement, covering the resale of up to 10,774,596 shares of common stock by selling stockholders, potentially generating $19.25 million.

CVI Investments, Inc. and Heights Capital Management, Inc. have reported beneficial ownership of approximately 4.9% of Plus Therapeutics, Inc. common stock, primarily through warrants.

Highbridge Capital Management, LLC has reported beneficial ownership of 7.1% of Plus Therapeutics, Inc. common stock, primarily through the exercise of warrants.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly reported a beneficial ownership of 6.9% in Plus Therapeutics, Inc., totaling 12,368,423 shares.

S.H.N. Financial Investments Ltd. has increased its beneficial ownership in Plus Therapeutics, Inc. to 1.51% of common stock.

AIGH Capital Management and Orin Hirschman have disclosed a 3.9% beneficial ownership stake in Plus Therapeutics, Inc., primarily through sole dispositive power over 1,283,681 shares including warrants.

The Hewlett Fund LP has filed an amended Schedule 13G, reporting zero beneficial ownership of common stock in Plus Therapeutics, Inc., indicating a complete divestment of its previous holdings.